L-Mont XL Tablet SR is a combination pharmaceutical formulation containing Ambroxol 75 mg, Levocetirizine 5 mg, and Montelukast 10 mg, designed for the management of respiratory conditions characterized by cough, allergic rhinitis, and bronchial asthma. Ambroxol acts as a mucolytic agent, facilitating the clearance of mucus by enhancing mucociliary transport and reducing sputum viscosity, thereby improving airway patency. Levocetirizine, a selective second-generation antihistamine, provides symptomatic relief from allergic manifestations such as sneezing, nasal congestion, and rhinorrhea by antagonizing peripheral H1 receptors without significant sedation. Montelukast, a leukotriene receptor antagonist, inhibits cysteinyl leukotriene-mediated inflammation and bronchoconstriction, contributing to the control of asthma symptoms and prevention of exercise-induced bronchospasm. The sustained-release formulation ensures prolonged therapeutic plasma concentrations, enhancing patient compliance through once-daily dosing. L-Mont XL Tablet SR is indicated for patients requiring combined mucolytic, anti-allergic, and anti-inflammatory therapy in conditions such as chronic bronchitis, allergic rhinitis, and mild to moderate asthma. It should be used under medical supervision, considering contraindications and potential drug interactions. Common adverse effects may include headache, gastrointestinal disturbances, and drowsiness. Regular monitoring and adherence to prescribed dosage are essential for optimal therapeutic outcomes.